A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

ClinicalTrials.gov ID: NCT00650468

Public ClinicalTrials.gov record NCT00650468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs. Long Term Corticosteroid Therapy With Prograf and CellCept in Primary Renal Transplant Patients

Study identification

NCT ID: NCT00650468
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 397 participants

Conditions and interventions

Conditions

Renal Transplantation

Interventions

tacrolimus Drug
CellCept Drug
steroids (methylprednisone or prednisone) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 1999
Primary completion: Nov 30, 2007
Completion: Nov 30, 2007
Last update posted: Nov 16, 2011

1999 – 2007

United States locations

U.S. sites: 29
U.S. states: 20
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72205	—
Not listed	Loma Linda	California	92354	—
Not listed	Los Angeles	California	90057	—
Not listed	Denver	Colorado	80262	—
Not listed	Chicago	Illinois	60637	—
Not listed	Lexington	Kentucky	40536	—
Not listed	New Orleans	Louisiana	70121	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Boston	Massachusetts	02111	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Omaha	Nebraska	68198	—
Not listed	New Brunswick	New Jersey	08903	—
Not listed	Buffalo	New York	14203	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Cleveland	Ohio	44106	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Providence	Rhode Island	02903	—
Not listed	Memphis	Tennessee	38163	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Galveston	Texas	77555	—
Not listed	San Antonio	Texas	78229	—
Not listed	Salt Lake City	Utah	84103	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Madison	Wisconsin	53792	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00650468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 16, 2011 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00650468 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →